Dr. Reddy’s Announces the Launch of Eszopiclone Tablets C-IV

  Dr. Reddy’s Announces the Launch of Eszopiclone Tablets C-IV

Business Wire

HYDERABAD, India -- April 16, 2014

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched
Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent
generic version of LUNESTA® (eszopiclone) tablets C-IV in the US market on
April 15, 2014, following the approval by the United States Food & Drug
Administration (USFDA).

The LUNESTA® (eszopiclone) tablets C-IV brand and generic combined had U.S.
sales of approximately $887 Million MAT for the most recent twelve months
ending in January 2014 according to IMS Health*.

Dr. Reddy’s Eszopiclone Tablets (C-IV) 1 mg is available in bottle counts of
30. Eszopiclone Tablets (C-IV) 2 mg and 3 mg are available in bottle counts of


This press release includes forward-looking statements, as defined in the U.S.
Private Securities Litigation Reform Act of 1995. We have based these
forward-looking statements on our current expectations and projections about
future events. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially. Such
factors include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the market
acceptance of and demand for our products, our growth and expansion,
technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially
different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary Products –
Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management and anti-infective. Major markets
include India, USA, Russia-CIS and Europe apart from other select geographies
within Emerging Markets.  For more information, log on to: www.drreddys.com

LUNESTA^® is a registered trademark of Sunovion Pharmaceuticals Inc.
*IMS National Sales Perspectives: Retail and Non-Retail MAT January 2014


Dr. Reddy’s Laboratories Ltd.
Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
Saunak Savla, +91-40-49002135
Milan Kalawadia (USA), +1 609-375-9831
SVS Chowdary, +91-40-49002448
Press spacebar to pause and continue. Press esc to stop.